Abstract: The present invention relates to a human ADARB2-derived cell-penetrating peptide and a cargo-molecule delivery system using the same, and provides a method for delivering cargo molecules into a cell, the method comprising a step for bringing a cargo-molecule transduction domain including the human ADARB2-derived RMAD1 or a variant thereof and a recombinant cargo molecule fused with the cargo molecule transduction domain into contact with cells. The cargo molecule transduction domain of the present invention not only can introduce cargo molecules into cells at a higher efficiency than existing cell-penetrating peptides, but is a polypeptide sequence derived from human proteins, and thus also has no risk of causing immune response problems. Thus the cargo molecule transduction domain is useful for delivering various polymer materials into human cells.

Abstract: The present disclosure relates to the technical field of cosmetics and discloses a retinol derivative composition and use thereof. The present disclosure provides the retinol derivative composition, including hydroxypinacolone retinoate and retinyl propionate, wherein the ratio of the hydroxypinacolone retinoate to the retinyl propionate in parts by mass is (5-40):9. The present disclosure utilizes the synergistic effect of the hydroxypinacolone retinoate and the retinyl propionate, can extremely significantly increase the expressions of important series of proteins related to aging, and has no cytotoxicity. Therefore, when the retinol derivative composition provided by the present disclosure is used in cosmetics and/or skin care products, the composition can reach a significant anti-aging effect with a low application amount and less skin irritation.

Abstract: A cosmetic composition includes a firming system that includes: a pectin; at least one powder; water; at least one fatty compound; and at least one plasticizer. The firming system when is spreadable and wherein upon drying the firming system forms a firming film that exhibits cohesion and adhesion when applied to a substrate. The pectin may comprise low methoxyl pectin, and the firming system may further include at least one monosaccharide, disaccharide or combination thereof. The composition may include a cosmetic carrier system wherein the firming system and cosmetic carrier system is in the form of liquidous or creamy type emulsion or an oil free serum for application to skin to ameliorate the signs of aging or a viscous liquidous emulsion or suspension for application as a makeup to keratinous tissue selected from skin, lashes and hair to confer firming to the keratinous tissue.

Abstract: A carrier phase, a neutral surfactant or a reaction product thereof, and a reaction product of a saccharide polymer and a fatty acid or a fatty ester may be formulated as consumer or industrial products of various types. The reaction product of the saccharide polymer may be obtained in the presence of water and a hydroxide base (optionally in the presence of the neutral surfactant). The saccharide polymer comprises a dextran, a dextrin compound, or any combination thereof, and the fatty acid comprises about 50 wt. % or above of one or more straight-chain fatty acids. Illustrative products may include adjuvants, foaming agents, hard surface cleaners, skin creams and lotions, body washes, shampoos, liquid soaps, sunscreens, hair sprays and gels, cosmetics, deodorants, and antiperspirants.

Abstract: Provided herein are compositions containing a polymer substrate and a fragrance, methods for preparing such compositions, and methods for using such compositions for providing scents to an environment, such as a room or a vehicle. For example, the polymer substrate may comprise an alkyl acrylate, including but not limited to methyl acrylate. For example, the fragrance may comprise a polar or nonpolar molecule, or a collection of polar and/or nonpolar molecules. The resulting composition provides a temperature-stable fragrance composition that can be used within vehicles, has low to no residual odor, and can be loaded with at least 90% by weight of fragrance (relative to the weight of the polymer substrate).

Abstract: A composite opacifier dispersion is provided, comprising: a dispersion medium; a processing surfactant; and a plurality of composite opacifier particles, wherein the composite opacifier particles comprise metal oxide particles that are partially or completely encapsulated by a polycaprolactone polymer; wherein the metal oxide particles are selected from the group consisting of zinc oxide, titanium oxide and mixtures thereof; wherein the metal oxide particles have a z average particle size of >100 nm as measured by dynamic light scattering; and wherein the composite opacifier particles have a z average particle size of >150 nm to 2,500 nm as measured by dynamic light scattering.

Abstract: An anhydrous composition for caring for and/or making up keratin materials, which is liquid and comprises: a) at least one organopolysiloxane elastomer powder coated with a silicone resin; b) at least one organopolysiloxane elastomer conveyed in a first oil; c) at least two fillers including polymethylsilsesquioxane and calcium aluminum borosilicate; and d) at least one second oil, which is a volatile hydrocarbon oil, wherein the composition does not comprise a wax and comprises more than 15 wt % of fillers, relative to the total weight of the composition.

Abstract: A composition includes mixed bacterial strains of Bacillus sp. pfbarrier 01 (KCTC 14628BP), Lactobacillus pentosus pfbio035 (KCTC 14684BP) and Lactobacillus sakei subsp. sakei pfbio005 (KCTC 14130BP), a culture solution thereof, or a compound extract thereof as an active ingredient to offer beneficial activities in improving skin wrinkles, moisturizing skin, strengthening skin barriers, and promoting regeneration of wounded skin. The composition poses non-cytotoxicity and high beneficial effects to improve skin wrinkles, moisturize skin, strengthen skin barriers, and help regeneration of wounded skin, which makes it highly applicable to the fields of foods and cosmetics. Besides, the composition is not only very safe for the human body but also has high stability.

Abstract: Disclosed are compositions and methods for their use that include a combination of escin, Ruscus aculeatus root extract, ammonium glycyrrhizate. Centella asiatica extract, hydrolyzed yeast protein, and Calendula officinalis flower extract.

Abstract: The present invention generally relates to formulations comprising a drug and biodegradable polymers that are compacted mechanically from a physical mixture to disrupt interconnected open channels for substantially longer drug release than non-compacted counterpart formulations and methods of use and manufacture thereof.

Abstract: Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregnant mother. Fibroblast growth factor is to correct structural defects of neural tissue.

Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more mucoadhesive polymers, a sodium alginate as well as at least one humectant so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. The sodium alginate containing eye insert may vary dissolution time on the ocular surface for a longer lasting relief, may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.

Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. The polymeric eye insert comprises at least one monovalent alginate layer and at least one multivalent salt layer. The at least one monovalent alginate layer is substantially free of the multivalent salt, and the at least multivalent salt layer is substantially free of the monovalent alginate.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: Pharmaceutical compositions are provided for pulmonary administration of a JAK inhibitor, and, for example, dry powder formulations that include a JAK inhibitor and an agglomerated lactose carrier. Methods of making and using the pharmaceutical composition, as well as kits and dosage forms are also provided.

Abstract: This invention outlines a novel substrate for delivery various biologically active substances by the mechanism of vaporizing the active component followed by inhalation for blood stream uptake by the lungs. The substrate composition and structure is particularly beneficial as it does not produce any toxic combustion products, unlike most vaping compositions currently available.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: The present invention includes systems, methods and compositions related to the production and use of chemically modified cannabinoid food and beverage additives having enhanced water solubility and stability.

Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

Abstract: The present invention provides for a method of transporting and preparing an injectable ice slurry for administration to a patient at a point of care comprising preparing a biocompatible solution comprising water and at least one component other than water, placing the biocompatible solution into a container, transporting the container with the biocompatible solution to the point of care, transforming the biocompatible solution into an injectable ice slurry at the point of care, and administering the injectable ice slurry to the patient at the point of care.

Abstract: A sprayable composition having one or more oil-in-water dispersions of (i) particles of one or more hydrophobic agent(s), (ii) one or more polymer or copolymer fragments, or combinations thereof, and (iii) an aqueous-solute fluid. The particles of one or more hydrophobic agent(s) are present in an amount from about 0.01% wt. to about 70% wt., the one or more polymer or copolymer fragments, or combinations thereof are present in an amount from about 0.01% wt. to about 10% wt., and the aqueous-solute fluid is present in an amount from about 1.0% wt. to about 98.5% wt., all based on the total weight of the composition. The one or more polymer or copolymer fragments, or combinations thereof, are sufficient to stabilize the particles of one or more hydrophobic agent(s) in the dispersion, at a level from about 0.05% w/w to about 70% w/w of the one or more hydrophobic agent(s), in the dispersion.

Abstract: Described are oil-in-water emulsions of (i) submicron particles of one or more hydrophobic agent(s), (ii) an emulsifier system comprising one or more nonionic surfactant(s) or emulsifier(s), and (iii) an aqueous-solute fluid. The submicron particles of one or more hydrophobic agent(s) are present in an amount from about 0.01% wt. to about 70% wt., the one or more nonionic surfactant(s) or emulsifier(s) are present in an amount from about 0.01% wt. to about 10% wt., and the aqueous-solute fluid is present in an amount from about 1.0% wt. to about 98.5% wt., all based on the total weight of the composition. The submicron particles of one or more hydrophobic agent(s) (i) have an average particle size from about 100 nm to less than about 1000 nm, (ii) have a solubility of less than about 0.1% by weight in water under standard conditions, and (iii) are 85% or more of a size within ±2.0 standard deviations, of the average particle size.

Abstract: Nanolipoprotein particles comprising at least a scaffold protein component and a membrane lipid component and related complexes, compositions, methods and systems are described, in which the membrane lipid component comprises at least one or more membrane forming lipids and one or more cationic lipids.

Abstract: Disclosed herein are novel dendritic structures that can be used in combination with other lipid components to form nanoparticles with nucleic acids. to facilitate the intracellular delivery of nucleic acids both in vitro and in vivo. Nanoparticle compositions comprising the compounds and methods for their use for treating or preventing diseases or conditions are also provided.

Abstract: A medical device for retrieval of kidney stone fragments from a urinary tract is provided. The medical device has a plurality of magnets arranged within a flexible sheath forming a flexible wire. The magnets are magnetically attached end-to-end and arranged with their magnetic polarities alternating in direction. The magnetization direction of each of the magnets is orthogonal to the length axis of the flexible wire. A removable inner stylet is situated within the flexible sheath allowing for modifiable flexibility of the wire. The medical device is dimensioned to be introduced into the urinary tract and standard endoscopic devices. The medical device is further dimensioned to allow for the wire with magnetically attached stone fragments to be retrieved from the urinary tract. The magnetic field along the length axis is sufficient to attract to the surface of the flexible wire superparamagnetic nanoparticles which have bound themselves to kidney stone fragments.

Abstract: An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile. Dosage units may also provide an immediate release component.

Abstract: There is a dire need for innovative nanomedicine-based solutions for safe and efficient thrombolysis with a non-toxic, biocompatible, and biodegradable thrombus-targeted carrier. In the present invention, polysaccharide hydrogel submicroparticles with remarkable biocompatibility were elaborated by the inverse miniemulsion/crosslinking method. They were functionalized with a fucoidan which has a nanomolar affinity for the P-selectin overexpressed on activated platelets and endothelial cells in vascular diseases. Surprisingly, the inventors show that rtPA (i.e. Alteplase) can be loaded onto the submicroparticles by adsorption, and its amidolytic and fibrinolytic activities were maintained in vitro and in vivo. Thrombus targeting potential of these particles was validated in microfluidic assay under arterial and venous blood shear rates on recombinant P-selectin and activated platelet aggregates.

Abstract: The present invention relates to the use of maltodextrin as an excipient. In particular, the present invention relates to the use of maltodextrin as an excipient in probiotic formulations. The present invention also relates to a method to provide a probiotics formulation with improved dispersibility and/or shelf life comprising adding maltodextrin to probiotic formulations.

Abstract: The invention provides pharmaceutical compositions comprising a piperidinyl-methyl-purine amine and their use for inhibiting NSD2 and treating a disease or condition, such as cancer.

Abstract: The present disclosure relates to a chemical composition and a method of manufacturing thereof. The chemical composition comprises: (a) a first component; (b) a second component surrounding the first component and enclosing the first component; and (c) an enteric coating forming an exterior of the chemical composition and enclosing the second component and the first component. The second component can consist essentially of a disintegrant; the disintegrant can comprise one or more salts selected from the group consisting of a carbonate salt, a bicarbonate salt, a hydrogendicarbonate salt, a hydrate of any one of the carbonate salt, the bicarbonate salt and the hydrogendicarbonate salt, and any combination thereof. The carbonate salt can be selected from the group consisting of sodium carbonate and potassium carbonate. The bicarbonate salt can be selected from the group consisting of sodium bicarbonate and potassium bicarbonate.

Abstract: Microparticles containing a core of therapeutic protein and a cortex of a biocompatible and biodegradable polymer, and methods of making and using the microparticles are provided. The extended release of a therapeutic protein from the microparticles in a physiological solution is demonstrated over an extended period of time.

Abstract: This invention relates to a Nanostructured Lipid Carrier (NLC) particle comprising a therapeutic agent encapsulated therein for ocular delivery of the therapeutic agent, wherein the Nanostructured Lipid Carrier comprises: (i) a solid outer shell comprising a solid lipid, and (ii) a liquid core comprising a liquid lipid; and wherein the core comprises the therapeutic agent. Compositions of the NLC particles, use of the NLC particles, methods of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.

Abstract: Provided herein are glycoprotein particles comprising one or more glycoproteins, or fragments thereof that enhance targeting of a particle to a cell or tissue. A glycoprotein particle as provided herein may be used for any application, including therapeutic and diagnostic treatments.

Abstract: A novel nanocomposite made of superparamagnetic nanoparticles, gold nanoparticles and reduced graphene oxide porous nanosheets is synthesized. The novelty of the nanocomposite lies in three main factors: the porosity of the reduced graphene oxide sheet, the magnetization of the superparamagnetic nanoparticles and the biocompatibility and near infrared absorbance of the gold nanoparticles all in one nanocomposite that does not disassemble when administered in the body. All of which are joined to create a whole and singular nanocomposite that can emit heat due to magnetic energy, become as biocompatible as possible and conceivably allow for near infrared absorbance penetration while the nanocomposite is fully assembled.

Abstract: Systems and methods of forming electrospun structures including pharmaceuticals are disclosed. An electrospun structure can include one or more polymers electrospun from a polymer solution comprising a pharmaceutical such that the pharmaceutical is dispersed throughout the one or more electrospun polymers. The pharmaceutical can include a cannabinoid, a phytocannabinoid, a terpene produced by a cannabis plant, or a combination thereof. The one or more electrospun polymer are configured to degrade over a predetermined time period to deliver the pharmaceutical over the predetermined time period.

Abstract: The invention provides pharmaceutical compositions of fluorocarbon emulsions and methods thereof that are useful for treating cancer, in particular in enhancing the effect of immunotherapy in cancer treatment.

Abstract: The present invention relates to the field of reduction of methane emission in ruminants. Particularly, it relates to the administration of limonene and propanediol mononitrate to a ruminant for reducing the production of methane emanating from the digestive activities of said ruminant.

Abstract: A method for improving cardiovascular health in a human subject includes administering a composition to the human subject identified as being at risk for cardiovascular disease. The composition includes macular xanthophylls. In certain instances, the composition may be provided as a single consumable including lutein, zeaxanthin, and meso-zeaxanthin. The single consumable may include 10 milligrams of lutein, 2 milligrams of zeaxanthin, and 10 milligrams of meso-zeaxanthin. In other instances, the composition may be provided as two or more consumable. The two or more consumable collectively including lutein, zeaxanthin, and meso-zeaxanthin.

Abstract: Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

Abstract: The present invention relates to the field of reduction of methane emission in ruminants. Particularly, it relates to the administration of gossypol and propanediol mononitrate to a ruminant for reducing the production of methane emanating from the digestive activities of said ruminant.

Abstract: The present disclosure generally relates to the treatment of subjects having Type 2 diabetes and/or chronic kidney disease or at risk of developing Type 2 diabetes and/or chronic kidney disease by administering a Hepatocyte Nuclear Factor 4 Alpha (HNF4A) agonist to the subject.

Abstract: Compositions in the form of a thermoformed extrudate in any suitable form allowing administration to an animal or a human being, comprising at least one natural or synthetic N-alkylamide as active substance and at least one support of natural origin chosen from the group consisting of amino acids, peptides, polypeptides, proteins, saccharides, lipids, their derivatives and their mixtures. And methods of forming such thermoformed extrudates.

Abstract: The present invention relates to improved topical composition of Colchicine or a pharmaceutically acceptable salt thereof as an active agent and, process of preparing such improved topical composition. The invention also relates to the use of said improved topical composition for prophylaxis and the treatment of acute gout flares.

Abstract: Provided are pharmaceutical compositions, formulations, products of manufacture and kits, and methods, for: mitigating, ameliorating, treating or preventing a proteostasis-based injury; selectively inducing only the ATF6 arm of the unfolded protein response in a cell, a tissue or in a mammal, wherein optionally the mammal is a human; protecting a mammalian heart or a mammalian tissue from an acute or a long term ischemia/reperfusion injury or damage; pharmacologically activating ATF6 or the ATF6 arm of the unfolded protein response in a cell or in vivo; comprising: administering to the cell, the tissue, the mammal or the individual in need thereof: (a) a compound as provided herein, for example, the exemplary compound 147.

Abstract: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum. The ablation may be a mechanical, electrical, thermal, radiative, or chemical ablation and may in some cases target a sensory nerve. The methods may, in some cases, comprise the step of administering an active agent directly to the small intestine in the subject, in particular administering the active agent directly to the duodenum. The active agents useful in the treatments described herein include analgesic agents and, in particular, antinociceptive agents such as capsaicin, resiniferatoxin, and their analogues.

Abstract: Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precursor thereof, to increase the concentration of threonate in the medium, where the increased concentration of threonate is sufficient to increase the concentration of magnesium in the cell. Also provided is a method that includes administering a threonate-containing compound, or a precursor thereof, to an individual, to increase synaptic density in the brain and/or to treat a neurological disorder, e.g., cognitive impairment. The threonate-containing compound of the present disclosure does not include magnesium threonate.

Abstract: An intravenous composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose: a) approximately 125 mg to approximately 175 mg ibuprofen in combination with approximately 475 mg to approximately 525 mg paracetamol; or b) approximately 275 mg to approximately 325 mg ibuprofen in combination with approximately 975 mg to approximately 1,025 mg paracetamol.

Abstract: The present specification relates to an osteogenesis-promoting agent and/or a therapeutic agent for bone diseases comprising a pharmaceutical and/or food composition for promoting bone formation and/or preventing, treating, and/or ameliorating bone diseases, comprising an agent promoting the activation of osteoblasts as an active ingredient. Specifically, it was revealed for the first time that treatment with a low concentration of bongkrekic acid and/or regulation of the activity of Opa1 (suppression of expression), Fis1 (increase of expression), and Bax (increase of expression) genes induce morphological changes and fission of mitochondria to promote bone regeneration and/or bone formation, and the active ingredients can be utilized as a pharmaceutical composition for promoting bone regeneration and/or bone formation and a pharmaceutical composition for preventing and/or treating bone diseases.